Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.

 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

National Glaucoma Research - Current Award

Raghu Krishnamoorthy

Raghu Krishnamoorthy, Ph.D.

University of North Texas Health Science Center
Fort Worth, TX

Title: Regulation of endothelin B receptor expression in glaucomatous optic neuropathy
Non-Technical Title: Role of endothelin receptors in glaucoma

Duration: April 1, 2008 - March 31, 2010
Award Type: Standard
Award Amount: $100,000


Summary:

This study will determine if endothelin receptors produce some of the nerve damage seen in glaucoma. Understanding how endothelin receptors damage nerve cells will provide valuable information for blocking these receptors and protecting nerve cells from further damage. This could lead to development of neuroprotective drugs to effectively treat glaucoma.

Details:

Glaucoma is a neurodegenerative disease in which a select group of nerve cells in the eye undergo cell death. Increase eye pressure due to poor drainage of a fluid inside the eye is a major cause of glaucoma. Hence, most medications for glaucoma are aimed at reducing the pressure within the eye by either better drainage or reducing the rate at which fluid is formed inside the eye. This has proved to be an effective way to treat glaucoma. However, despite reducing the pressure, sometimes the nerve cells in the eye continue to die slowly. It would be very beneficial if we have additional approaches called neuroprotection (meaning: protection of nerve cells) to more effectively treat glaucoma. Scientific studies have shown that there is an increase in a protein called endothelin receptors in glaucoma patients. The proposed study will determine if endothelin receptors produce some of the nerve damage seen in glaucoma. Understanding how endothelin receptors are damaging to nerve cells, will provide valuable information to block these receptors and thereby provide protection to nerve cells in the eye from further damage. This could lead to development of neuroprotection drugs as additional treatments to effectively treat glaucoma.